EBMT 2023 | Vedolizumab for GI acute GvHD prophylaxis after allogeneic transplantation
James Ferrara, MD, DSc, Icahn School of Medicine at Mount Sinai, New York City, NY, outlines the mechanism of action of vedolizumab, a drug currently under evaluation in a Phase III study for the prophylaxis of lower gastrointestinal (GI) acute graft-versus-host disease (GvHD; NCT03657160). This interview took place at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
We’re very excited actually about the Van Bekkum Award, which looked at vedolizumab as a prophylactic strategy to prevent GI GvHD. Vedolizumab is not really an immunosuppressant, but it directs the traffic of T-cells away from the GI tract. It blocks that trafficking and with that blockade, we get much better GI tract protection and therefore better long-term outcomes. So, I think that this is actually a very important advance for GvHD prevention...
We’re very excited actually about the Van Bekkum Award, which looked at vedolizumab as a prophylactic strategy to prevent GI GvHD. Vedolizumab is not really an immunosuppressant, but it directs the traffic of T-cells away from the GI tract. It blocks that trafficking and with that blockade, we get much better GI tract protection and therefore better long-term outcomes. So, I think that this is actually a very important advance for GvHD prevention.
Read more...
Disclosures
US patent for serum biomarkers of GVHD
